These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 25564105)
21. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial. McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D; Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586 [TBL] [Abstract][Full Text] [Related]
22. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization. Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181 [TBL] [Abstract][Full Text] [Related]
23. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096 [TBL] [Abstract][Full Text] [Related]
24. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315 [TBL] [Abstract][Full Text] [Related]
25. Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial. Socias ME; Cui Z; Le Foll B; Lei J; Stewart S; Anand R; Jutras-Aswad D HIV Med; 2024 Jul; 25(7):817-825. PubMed ID: 38506171 [TBL] [Abstract][Full Text] [Related]
26. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915 [TBL] [Abstract][Full Text] [Related]
27. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients. Vicknasingam B; Dazali MN; Singh D; Schottenfeld RS; Chawarski MC Drug Alcohol Depend; 2015 Jul; 152():164-9. PubMed ID: 25935736 [TBL] [Abstract][Full Text] [Related]
28. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000 [TBL] [Abstract][Full Text] [Related]
29. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828 [TBL] [Abstract][Full Text] [Related]
30. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial. Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321 [TBL] [Abstract][Full Text] [Related]
31. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy. Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423 [TBL] [Abstract][Full Text] [Related]
32. HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. Meade CS; Weiss RD; Fitzmaurice GM; Poole SA; Subramaniam GA; Patkar AA; Connery HS; Woody GE J Acquir Immune Defic Syndr; 2010 Sep; 55(1):65-72. PubMed ID: 20393347 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Webster L; Hjelmström P; Sumner M; Gunderson EW J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785 [TBL] [Abstract][Full Text] [Related]
35. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018 [TBL] [Abstract][Full Text] [Related]
36. Buprenorphine alone or with naloxone: Which is safer? Kelty E; Cumming C; Troeung L; Hulse G J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352 [TBL] [Abstract][Full Text] [Related]
37. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Rudolph KE; Williams NT; Goodwin ATS; Shulman M; Fishman M; Díaz I; Luo S; Rotrosen J; Nunes EV Drug Alcohol Depend; 2022 Oct; 239():109609. PubMed ID: 36075154 [TBL] [Abstract][Full Text] [Related]
38. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. Woody GE; Bruce D; Korthuis PT; Chhatre S; Poole S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Metzger D; Ling W J Acquir Immune Defic Syndr; 2014 Jul; 66(3):288-93. PubMed ID: 24751432 [TBL] [Abstract][Full Text] [Related]
39. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689 [TBL] [Abstract][Full Text] [Related]
40. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia. Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]